MRTX - Jones Research sees Amgen FDA issues reading through to Mirati
2023-10-03 16:35:34 ET
More on Mirati Therapeutics
- Mirati: Expansion Of Adagrasib With sNDA And Combination Studies
- Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript
- Mirati stock climbs 10% ahead of data presentation, FDA meeting on rival drug
- Mirati CFO leaving company in wake of CEO departure
For further details see:
Jones Research sees Amgen FDA issues reading through to Mirati